ATE406881T1 - Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung - Google Patents

Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Info

Publication number
ATE406881T1
ATE406881T1 AT02733811T AT02733811T ATE406881T1 AT E406881 T1 ATE406881 T1 AT E406881T1 AT 02733811 T AT02733811 T AT 02733811T AT 02733811 T AT02733811 T AT 02733811T AT E406881 T1 ATE406881 T1 AT E406881T1
Authority
AT
Austria
Prior art keywords
alpha
beta unsaturated
radiation
toxicity
arylsulphones
Prior art date
Application number
AT02733811T
Other languages
German (de)
English (en)
Inventor
Premkumar Reddy
Ramana Reddy
Stephen Cosenza
Lawrence Helson
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc filed Critical Univ Temple
Application granted granted Critical
Publication of ATE406881T1 publication Critical patent/ATE406881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02733811T 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung ATE406881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28

Publications (1)

Publication Number Publication Date
ATE406881T1 true ATE406881T1 (de) 2008-09-15

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733811T ATE406881T1 (de) 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Country Status (10)

Country Link
US (1) US6667346B2 (enExample)
EP (1) EP1370253B8 (enExample)
JP (1) JP4302986B2 (enExample)
KR (1) KR100850331B1 (enExample)
AT (1) ATE406881T1 (enExample)
AU (1) AU2002305942B2 (enExample)
CA (1) CA2439288C (enExample)
DE (1) DE60228692D1 (enExample)
IL (2) IL157541A0 (enExample)
WO (1) WO2002069892A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2424884C (en) 2000-10-05 2009-12-15 E. Premkumar Reddy Substituted (e)-styryl benzylsulfones for treating proliferative disorders
ATE517626T1 (de) * 2002-02-28 2011-08-15 Univ Temple Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen
MXPA04008356A (es) * 2002-02-28 2005-09-12 Univ Temple (e)-2,6-dialcoxiestiril bencilsulfonas sustituidas con un grupo amino y en la posicion 4 para tratar trastornos poliferativos.
HUE032523T2 (en) * 2003-11-14 2017-09-28 Temple Univ - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for the treatment of proliferative disorders
CA2546445A1 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
ES2609084T3 (es) * 2004-03-16 2017-04-18 Temple University - Of The Commonwealth System Of Higher Education Derivados de fenoxi y feniltio sustituidos para tratar trastornos proliferativos
CA2577309C (en) 2004-06-24 2013-10-22 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
WO2006010152A2 (en) * 2004-07-19 2006-01-26 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
AU2006204103B2 (en) * 2005-01-05 2011-11-24 Temple University Of The Commonwealth System Of Higher Education Treatment of drug-resistant proliferative disorders
PT1896401E (pt) * 2005-02-25 2013-07-17 Univ Temple Síntese de sulfuretos, sulfonas, sulfóxidos e sulfonamidas não saturados
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
KR101309903B1 (ko) * 2005-07-29 2013-09-17 온코노바 테라퓨틱스, 인코포레이티드 방사선 보호 α,β 불포화 아릴설폰 제형
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
CA2659222C (en) * 2006-07-28 2012-01-31 Onconova Therapeutics, Inc. Formulations of radioprotective .alpha., .beta. unsaturated aryl sulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
US8273787B2 (en) * 2006-09-15 2012-09-25 Onconova Therapeutics, Inc Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
WO2008076270A2 (en) * 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
CA2738909A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
CN102231984A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗化疗化合物的造血防护
EP2373993B1 (en) * 2008-12-16 2015-08-05 Onconova Therapeutics, Inc. Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
US20120100100A1 (en) 2009-05-13 2012-04-26 Sharpless Norman E Cyclin dependent kinase inhibitors and methods of use
CN104320971A (zh) * 2010-03-24 2015-01-28 安哥洛华治疗公司 用于预防和治疗创伤的组合物和方法
CN102821605B (zh) 2010-03-26 2015-11-25 安哥洛华治疗公司 改进的稳定的（e）-4-羧基苯乙烯基-4-氯苄基砜水性制剂
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
US10207989B2 (en) 2012-09-20 2019-02-19 Temple University—Of the Commonwealth System of Higher Education Substituted alkyl diaryl derivatives, methods of preparation and uses
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
CN105473140B (zh) 2013-03-15 2018-04-10 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
WO2015101678A2 (en) * 2014-01-06 2015-07-09 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
US10383831B2 (en) 2015-08-03 2019-08-20 Temple University—Of the Commonwealth System of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
CA3127373A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP4001263B1 (en) * 2019-07-18 2024-03-27 Huaxiashengsheng Pharmaceutical Beijing Co., Ltd. Carbamate-substituted styryl sulfone compound, preparation method, and application thereof
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE284386T1 (de) * 1997-10-03 2004-12-15 Univ Temple Styrolsulfone als antikrebsmittel
US6201154B1 (en) 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
CA2366750C (en) 1999-04-02 2010-06-01 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
JP2002541101A (ja) * 1999-04-02 2002-12-03 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
AU2001251391A1 (en) * 2000-04-06 2001-10-23 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
IL157540A0 (en) * 2001-02-28 2004-03-28 Univ Temple N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2439288A1 (en) 2002-09-12
US6667346B2 (en) 2003-12-23
KR100850331B1 (ko) 2008-08-04
WO2002069892A3 (en) 2002-11-07
WO2002069892A2 (en) 2002-09-12
JP2004525908A (ja) 2004-08-26
EP1370253B1 (en) 2008-09-03
AU2002305942B2 (en) 2006-10-26
KR20030086596A (ko) 2003-11-10
IL157541A (en) 2010-05-31
JP4302986B2 (ja) 2009-07-29
EP1370253A4 (en) 2005-08-17
EP1370253B8 (en) 2008-11-26
IL157541A0 (en) 2004-03-28
CA2439288C (en) 2011-08-09
EP1370253A2 (en) 2003-12-17
US20030060505A1 (en) 2003-03-27
DE60228692D1 (de) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE406881T1 (de) Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EA200000087A1 (ru) Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
AR032912A1 (es) Formulacion farmaceutica
Capizzi The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (ethyol®)
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
JP2008519047A5 (enExample)
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
MXPA03003354A (es) Dispositivos medicos revestidos para el tratamiento de una enfermedad vascular.
Montoro et al. Infrared LED irradiation photobiomodulation of oxidative stress in human dental pulp cells
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
Anné et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
DE60044092D1 (de) Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
Blakley et al. Differences in Ototoxicity across Species.
ATE442188T1 (de) Bestrahlungseinrichtung
WO2009062128A3 (en) Combination drug therapy for the treatment of cancer
EP1374873A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR SUPPRESSING THE SIDE EFFECTS OF RADIATION THERAPY AND CHEMOTHERAPY

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties